このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
Stoke Therapeutics マネジメント
マネジメント 基準チェック /44
Stoke Therapeutics'の CEO はEd Kayeで、 Oct2017年に任命され、 の在任期間は 6.67年です。 の年間総報酬は$ 3.53Mで、 17.7%給与と82.3%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.052%を直接所有しており、その価値は$ 421.18K 。経営陣と取締役会の平均在任期間はそれぞれ4.7年と5.8年です。
主要情報
Ed Kaye
最高経営責任者
US$3.5m
報酬総額
| CEO給与比率 | 17.7% |
| CEO在任期間 | 6.8yrs |
| CEOの所有権 | 0.05% |
| 経営陣の平均在職期間 | 4.8yrs |
| 取締役会の平均在任期間 | 5.8yrs |
経営陣の近況
Recent updates
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Jun 14It Looks Like Stoke Therapeutics, Inc.'s (NASDAQ:STOK) CEO May Expect Their Salary To Be Put Under The Microscope
May 30
Stoke Therapeutics: Positive Dravet Data Sends Shares Soaring, One For The Watchlist
Apr 04Here's Why We're Watching Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Situation
Mar 21We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Dec 07Party Time: Brokers Just Made Major Increases To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Earnings Forecasts
May 09Analysts Are Upgrading Stoke Therapeutics, Inc. (NASDAQ:STOK) After Its Latest Results
May 06Stoke Therapeutics (NASDAQ:STOK) Is In A Strong Position To Grow Its Business
May 02We're Interested To See How Stoke Therapeutics (NASDAQ:STOK) Uses Its Cash Hoard To Grow
Dec 13Companies Like Stoke Therapeutics (NASDAQ:STOK) Can Afford To Invest In Growth
Aug 14Stoke Therapeutics GAAP EPS of -$0.63 beats by $0.05, revenue of $3.2M beats by $0.18M
Aug 08We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Apr 29Stoke Therapeutics (NASDAQ:STOK) Is In A Good Position To Deliver On Growth Plans
Jan 13We're Not Very Worried About Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Sep 30We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Jun 16Stoke Therapeutics EPS misses by $0.02
May 10We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Mar 03Stoke Therapeutics: A Preclinical Biopharma With A Multibillion Dollar Market Cap
Dec 14Stoke Therapeutics prices $97.5M public offering
Nov 20Stoke Therapeutics -2.7% AH, proposes public offering
Nov 18We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
Nov 18Stoke Therapeutics EPS in-line
Nov 12CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$109m |
| Dec 31 2023 | US$4m | US$626k | -US$105m |
| Sep 30 2023 | n/a | n/a | -US$103m |
| Jun 30 2023 | n/a | n/a | -US$105m |
| Mar 31 2023 | n/a | n/a | -US$99m |
| Dec 31 2022 | US$6m | US$596k | -US$101m |
| Sep 30 2022 | n/a | n/a | -US$100m |
| Jun 30 2022 | n/a | n/a | -US$96m |
| Mar 31 2022 | n/a | n/a | -US$94m |
| Dec 31 2021 | US$9m | US$568k | -US$86m |
| Sep 30 2021 | n/a | n/a | -US$76m |
| Jun 30 2021 | n/a | n/a | -US$67m |
| Mar 31 2021 | n/a | n/a | -US$58m |
| Dec 31 2020 | US$5m | US$549k | -US$52m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$43m |
| Mar 31 2020 | n/a | n/a | -US$38m |
| Dec 31 2019 | US$668k | US$477k | -US$32m |
| Sep 30 2019 | n/a | n/a | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$21m |
| Mar 31 2019 | n/a | n/a | -US$16m |
| Dec 31 2018 | US$1m | US$464k | -US$13m |
報酬と市場: Edの 総報酬 ($USD 3.53M ) は、 US市場 ($USD 3.40M ) の同様の規模の企業の平均とほぼ同じです。
報酬と収益: Edの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Ed Kaye (75 yo)
6.8yrs
在職期間
US$3,533,210
報酬
Dr. Edward M. Kaye, also known as Ed, M.D., Ph.D. has been Special Regulatory and Scientific Advisor of Sarepta Therapeutics, Inc. since June 28, 2017. He serves as Independent Director at Avidity Bioscien...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$3.53m | 0.052% $ 342.1k | |
| Co-Founder & Independent Director | no data | US$198.33k | 0.78% $ 5.1m | |
| Chief Medical Officer | 6.8yrs | US$1.65m | 0.0048% $ 31.5k | |
| Co-Founder & Senior VP of Discovery Research | no data | データなし | データなし | |
| Chief Financial Officer | less than a year | データなし | データなし | |
| COO & Chief Business Officer | 6.8yrs | US$869.86k | 0% $ 0 | |
| Head of Investor Relations | no data | データなし | データなし | |
| Corporate Secretary & General Counsel | 3.5yrs | データなし | 0.0050% $ 32.9k | |
| Chief Communications Officer | 3.5yrs | データなし | データなし | |
| Chief Human Resources Officer | 4.8yrs | データなし | データなし | |
| Chief Regulatory Officer | 5.6yrs | データなし | データなし | |
| Chief Commercial Officer | less than a year | データなし | データなし |
4.8yrs
平均在職期間
54.5yo
平均年齢
経験豊富な経営陣: STOKの経営陣は 経験豊富 であると考えられます ( 4.7年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| CEO & Director | 6.8yrs | US$3.53m | 0.052% $ 342.1k | |
| Co-Founder & Independent Director | 10.1yrs | US$198.33k | 0.78% $ 5.1m | |
| Independent Chairman of the Board | 9yrs | US$237.33k | 3.6% $ 23.8m | |
| Independent Director | 8.8yrs | US$198.33k | 0.034% $ 227.8k | |
| Independent Director | less than a year | US$394.03k | 0% $ 0 | |
| Independent Director | 3.9yrs | US$199.33k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$206.83k | 0% $ 0 | |
| Independent Director | 5.1yrs | US$209.33k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$211.83k | 0.061% $ 402.2k |
5.8yrs
平均在職期間
61yo
平均年齢
経験豊富なボード: STOKの 取締役会 は 経験豊富 であると考えられます ( 5.8年の平均在任期間)。